Chardan Capital Maintains Buy on Monopar Therapeutics, Maintains $100 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $100 price target.
Chardan Capital analyst Keay Nakae maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $100 price target.